Find in Library

The novel coronavirus disease 2019 (COVID-19) is highly contagious and rapidly spreading all over the world. COVID-19 patients might present with higher susceptibility to fungal co-infection. Mucormycosis is a life-threatening fungal disease characterized by vascular invasion by hyphae, leading to thrombosis and necrosis. Currently, COVID-19–associated mucormycosis (CAM) is creating a threat to patient's life in the community and is considered a fatal clinical entity in the Indian subcontinent. Mucormycosis is emerging as a matter of concern in COVID-19 patients with poorly controlled diabetes mellitus and other comorbidities as risk factors. Here, a 48-year-old man previously admitted to the COVID hospital due to severe acute respiratory syndrome coronavirus 2 infection presented with foreign body sensation and was later diagnosed with primary mucormycosis at the palatine tonsils. Early diagnosis and prompt treatment with surgery followed by liposomal amphotericin B are essential for the successful management of the CAM.